药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Pirbuterol
Pinaverium
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Pinaverium.
Pirbuterol
Lurasidone
The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Mirabegron.
Pirbuterol
Tetrahydropalmatine
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Tetrahydropalmatine.
Pirbuterol
Lacidipine
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Lacidipine.
Pirbuterol
Delafloxacin
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Delafloxacin.
Pirbuterol
Acrivastine
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Acrivastine.
Pirbuterol
Vilanterol
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Vilanterol.
Pirbuterol
Ezogabine
The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Mirabegron.
Pirbuterol
Pipemidic acid
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Pipemidic acid.
Pirbuterol
Rufloxacin
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Rufloxacin.
Pirbuterol
Piromidic acid
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Piromidic acid.
Pirbuterol
Lorajmine
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Lorajmine.
Pirbuterol
Oxolinic acid
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Oxolinic acid.
Pirbuterol
Prajmaline
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Prajmaline.
Pirbuterol
Cibenzoline
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Cibenzoline.
Pirbuterol
Pilsicainide
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Pilsicainide.
Pirbuterol
Givinostat
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Givinostat.
Pirbuterol
Temefos
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Temefos.
Pirbuterol
Prulifloxacin
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Prulifloxacin.
Pirbuterol
CUDC-907
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with CUDC-907.